Pathfinders in Biopharma

46 Episodes

1. ECM: Robust End to Year, Despite Previous Volatility

   Published: 31/10/2023
2. Biotech Halftime Report: A Winding Road Ahead

   Published: 26/09/2023
3. The Urgent Need to Address the Youth Mental Health Landscape

   Published: 17/08/2023
4. Website Traffic Reveals Biopharma Sales Trends

   Published: 7/08/2023
5. When to Call it Quits: VCs Making Tough Decisions in a Tough Market

   Published: 13/07/2023
6. How Biotech M&A is Redefining the Strategic Landscape

   Published: 23/06/2023
7. Healthcare Should Get Ready for ‘Fast and Furious’ M&A

   Published: 8/06/2023
8. Innovation and Growth: Key Ingredients to Healthcare M&A

   Published: 7/06/2023
9. Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?

   Published: 2/06/2023
10. Global Blood Therapeutics Commitment to Sickle-Cell Innovation

    Published: 22/05/2023
11. Is This the Breakthrough Moment for Genetic Medicine?

    Published: 13/04/2023
12. The Hidden Revolution Set to Turn US Healthcare on its Head

    Published: 26/01/2023
13. The Big Picture for Biotech

    Published: 13/12/2022
14. Why Biopharma Investment Requires a Different Mindset

    Published: 22/11/2022
15. The Optimism Behind the Biopharma Market

    Published: 3/10/2022
16. Biotech Investors: How to Find Value in a Bear Market

    Published: 21/03/2022
17. A call to action: Global Blood Therapeutics on tackling orphan disease

    Published: 8/12/2021
18. Ionis: Raising The Bar For ESG

    Published: 28/10/2021
19. Biotech and Big Pharma: Blueprint for Successful Partnership

    Published: 30/09/2021
20. What’s Material in ESG for Biopharma Firms?

    Published: 4/05/2021